Risk of disease progression (PD) following discontinuation of BRAF±MEK targeted therapies for reasons other than PD in patients (pts) with metastatic or unresectable melanoma.

Francesca Corti, Lorenza Di Guardo, Marta Bini et al.|Journal of Clinical Oncology|2020

Cited by 4